International Stem Cell Corporation (ISCO) Fair Value 2026

ISCO · Biotechnology ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.0 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (26/100)

Quick Summary — As of 2026-08-27, International Stem Cell Corporation (ISCO) trades at $0.49, versus a $0.64 median fair value across its 2 active models — 29.7% above the current price. QOC: 6.0/10. Value Trap Risk: 26/100 (LOW). 2/13 models active. Within that set, the Bayesian DCF component alone returns $0.51.

Key Facts

Ticker
ISCO
Price
$0.49
Quality Score
6.0/10
Value Trap Risk
26/100
Models Active
2/13
Last Updated
Strength: RCMH-DCF suggests +56.2% upside with 56% confidence
Risk: Limited model coverage (2/13) may reduce confidence

Is International Stem Cell Corporation (ISCO) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, International Stem Cell Corporation (ISCO) appears undervalued as of : the median of 2 independent fair value estimates is $0.64, 29.7% above the current price of $0.49. Estimates range from $0.51 to $0.77. ISCO scores 6.0/10 on fundamental quality and 26/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. ISCO’s +29.7% gap is wider than that market norm, and the Biotechnology sector median is -64.8%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy International Stem Cell Corporation Stock in 2026? →

What Fair Value Does Each Model Give ISCO?

2 Intrinsic Value Models vs. Current Price ($0.49)

Core Models (Unlocked)
Model Fair Value Upside
Intrinsic · High Conviction
 $0.51 +3.1%
Intrinsic · High Conviction
 $0.77 +56.2%

All Models Active

All 2 models are displayed above.

What Is International Stem Cell Corporation (ISCO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, International Stem Cell Corporation presents a highly debated valuation profile at its current price of $0.49. The median intrinsic value is estimated at $0.64 (+29.7% median upside), masking a wide model spread between the 1 bullish models and 0 bearish models. Model dispersion is worth noting: RCMH-DCF targets $0.77 (+56.2%), versus Bayesian DCF at $0.51 (+3.1%). This +53.1% range highlights the importance of multi-model analysis rather than relying on any single methodology.

What Do the Models Say About ISCO?

2 of 13 models are currently active for ISCO. All 2 active models suggest the stock trades below fair value. Taken together, their median fair value for ISCO is $0.64 — the figure CirclFi publishes as this stock's fair value. One component of that median, the Bayesian DCF, returns $0.51 on its own, implying +3.1% upside from the current price. See which stocks rank higher →

How Does ISCO Rank in Biotechnology?

Among 620 Biotechnology stocks, ISCO ranks #150 by Quality of Company score. CirclFi's QOC score of 6.0/10 evaluates 32 fundamental signals. A score of 6.0 reflects mixed fundamentals.

See all Most Undervalued Biotechnology Stocks →

The Biotechnology sector introduces analytical considerations specific to biotechnology enterprise businesses. For International Stem Cell Corporation, metrics like R&D burn rate provide important context that general-purpose valuation models may underweight.

Is ISCO a Value Trap?

CirclFi's Value Trap algorithm assigns ISCO a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for International Stem Cell Corporation. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Deep Alpha Valuation Engine, International Stem Cell Corporation scores 6.0 out of 10 on our 32-signal quality assessment, a solid rating that maintains reasonable quality metrics with some areas for improvement. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.

The gap between the most bullish and bearish model spans +53.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every ISCO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across ISCO's 2 active models, average confidence is 62%. Moderate confidence indicates reasonable fit.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy International Stem Cell Corporation Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Biotechnology Stocks Should You Also Analyze?

11 related Biotechnology stocks with 13-model coverage

RANIRani Therapeutics Holdings, Inc.QOC 6.0CYTKCytokinetics, IncorporatedQOC 6.0NUVBNuvation Bio Inc.QOC 6.0ATNMActinium Pharmaceuticals, Inc.QOC 6.0CAICaris Life Sciences, Inc.QOC 6.0TNXPTonix Pharmaceuticals Holding Corp.QOC 5.9BLTEBelite Bio, IncQOC 5.0KPRXKiora Pharmaceuticals, Inc.QOC 4.5PYPDPolyPid Ltd.QOC 2.0EXELExelixis, Inc.QOC 9.6INCYIncyte CorporationQOC 9.5

Read investment analysis: RANI · CYTK · NUVB · ATNM · CAI · TNXP · BLTE · KPRX · PYPD · EXEL · INCY

Which Other Stocks Have a Similar Quality Score to ISCO?

6 companies across all industries closest to ISCO’s Quality of Company score of 6.0/10.

BTCYBiotricity, Inc.QOC 6.0SKINSkinHealth Systems Inc.QOC 6.0PRMPerimeter Solutions, Inc.QOC 6.0OSGOctave Specialty Group, Inc.QOC 6.0HYLNHyliion Holdings Corp.QOC 6.0NVDANVIDIA CorporationQOC 10.0

Read investment analysis: BTCY · SKIN · PRM · OSG · HYLN · NVDA

Where Does ISCO Sit in CirclFi's Biotechnology Rankings?

ISCO is ranked against every other Biotechnology stock CirclFi covers in each of these screens.

See all Biotechnology stocks ranked →

What Else Do Investors Ask About International Stem Cell Corporation’s Valuation?

What is International Stem Cell Corporation's intrinsic value in 2026?

CirclFi puts International Stem Cell Corporation (ISCO)'s intrinsic value at $0.64 — the median of 2 independent model estimates as of 2026-08-27, ranging from $0.51 to $0.77. One component of that median, the Bayesian DCF, runs 10,000 Monte Carlo simulations with jump-diffusion and returns $0.51 on its own. The Quality of Company score is 6.0/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is ISCO overvalued or undervalued right now?

At $0.49, 2 of 2 active models suggest ISCO may be undervalued, while 0 indicate potential overvaluation. The median of all 2 fair value estimates is $0.64, 29.7% above the current price of $0.49 — a consensus view that ISCO is undervalued. The assessment depends on which methodology best fits International Stem Cell Corporation's business model in Biotechnology.

What does a Quality of Company score of 6.0 mean for ISCO?

International Stem Cell Corporation's QOC of 6.0/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on ISCO?

CirclFi analyzes ISCO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is ISCO a value trap in 2026?

International Stem Cell Corporation's Value Trap score is 26/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, International Stem Cell Corporation (ISCO) has a median fair value of $0.64 — 29.7% above the current price of $0.49 — as of 2026-08-27.” Source: circlfi.com/stock/ISCO/ · Methodology
Primary sources for this ISCO valuation

Market data for ISCO as of ; valuations recomputed .